198 related articles for article (PubMed ID: 21115933)
1. Comparative effect of finasteride and dutasteride on chromogranin A levels.
Sciarra A; Salciccia S; Nesi G; Cattarino S; Alfarone A; Gentilucci A; Gentile V
Anticancer Res; 2010 Nov; 30(11):4737-42. PubMed ID: 21115933
[TBL] [Abstract][Full Text] [Related]
2. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
3. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
4. The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.
Mačukat IR; Spanjol J; Orlič ZC; Butorac MZ; Marinovič M; Ćupič DF
Coll Antropol; 2014 Sep; 38(3):835-9. PubMed ID: 25420363
[TBL] [Abstract][Full Text] [Related]
5. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
6. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
7. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
8. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
9. [The effects of dutasteride on voiding and storage symptoms in men with benign prostatic hyperplasia].
Tsukamoto T; Shirai T; Sakamoto S; Akiyama A; Takeuchi H; Yajima M; Terao T; Endo Y
Hinyokika Kiyo; 2010 Dec; 56(12):677-82. PubMed ID: 21273805
[TBL] [Abstract][Full Text] [Related]
10. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
12. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
13. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
Guess HA; Heyse JF; Gormley GJ; Stoner E; Oesterling JE
Urol Clin North Am; 1993 Nov; 20(4):627-36. PubMed ID: 7505970
[TBL] [Abstract][Full Text] [Related]
14. Expectant management of localized prostate cancer--who, what, when, where and how?
Ehdaie B
J Urol; 2012 Sep; 188(3):696-7. PubMed ID: 22818346
[No Abstract] [Full Text] [Related]
15. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
16. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
17. Effect of dutasteride on microvessel density in benign prostatic hyperplasia.
Sugie S; Mukai S; Tsukino H; Iwamoto H; Kobayashi T; Toda Y; Kamoto T
In Vivo; 2014; 28(3):355-9. PubMed ID: 24815838
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
19. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of men on finasteride.
Gormley GJ
Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
